Trial Outcomes & Findings for Pilot Clinical Investigation Evaluating the Safety and Performance of RGn550 in Treating Sportspeople Suffering From Acute Concussion Syndrome (NCT NCT05647304)

NCT ID: NCT05647304

Last Updated: 2025-03-10

Results Overview

Percentage of patients with at least one ADE

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

50 participants

Primary outcome timeframe

Throughout the investigation (from Day 0 to Day 52)

Results posted on

2025-03-10

Participant Flow

Recruitment period : 11 October 2022 - 02 May 2023 One site located in France

Participant milestones

Participant milestones
Measure
5 Hz-PWM
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Overall Study
STARTED
26
24
Overall Study
COMPLETED
25
24
Overall Study
NOT COMPLETED
1
0

Reasons for withdrawal

Reasons for withdrawal
Measure
5 Hz-PWM
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Overall Study
Withdrawal by Subject
1
0

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Total
n=50 Participants
Total of all reporting groups
Age, Continuous
24.9 years
STANDARD_DEVIATION 5.2 • n=26 Participants
25.1 years
STANDARD_DEVIATION 5.1 • n=24 Participants
25.0 years
STANDARD_DEVIATION 5.1 • n=50 Participants
Sex: Female, Male
Female
3 Participants
n=26 Participants
3 Participants
n=24 Participants
6 Participants
n=50 Participants
Sex: Female, Male
Male
23 Participants
n=26 Participants
21 Participants
n=24 Participants
44 Participants
n=50 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
France
26 participants
n=26 Participants
24 participants
n=24 Participants
50 participants
n=50 Participants
Time between concussion and inclusion
2.4 days
STANDARD_DEVIATION 0.5 • n=26 Participants
2.3 days
STANDARD_DEVIATION 0.4 • n=24 Participants
2.3 days
STANDARD_DEVIATION 0.5 • n=50 Participants
Concussion history
2.0 concussion
STANDARD_DEVIATION 2.1 • n=26 Participants
1.4 concussion
STANDARD_DEVIATION 1.6 • n=24 Participants
1.7 concussion
STANDARD_DEVIATION 1.9 • n=50 Participants

PRIMARY outcome

Timeframe: Throughout the investigation (from Day 0 to Day 52)

Population: Patients randomized and treated at least once (at inclusion visit)

Percentage of patients with at least one ADE

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Incidence of RGn550's Adverse Device Effects (ADEs)
10 Participants
10 Participants

SECONDARY outcome

Timeframe: Throughout the investigation (from Day 0 to Day 52)

Population: Patients randomized and treated at least once (at inclusion visit)

Percentage of patients with at least one ADE per severity (mild, moderate and severe)

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Incidence of RGn550's ADEs Per Severity (Mild, Moderate and Severe)
Patients who had at least one mild ADE
10 Participants
10 Participants
Incidence of RGn550's ADEs Per Severity (Mild, Moderate and Severe)
Patients who had at least one moderate ADE
0 Participants
0 Participants
Incidence of RGn550's ADEs Per Severity (Mild, Moderate and Severe)
Patients who had at least one severe ADE
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Throughout the investigation (from Day 0 to Day 52)

Population: Patients randomized and treated at least once (at inclusion visit)

Percentage of patients with at least one AE

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Incidence of RGn550's Adverse Events (AEs)
12 Participants
10 Participants

SECONDARY outcome

Timeframe: Throughout the investigation (from Day 0 to Day 52)

Population: Patients randomized and treated at least once (at inclusion visit)

Percentage of patients with at least one DD

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Incidence of RGn550's Device Deficiencies (DDs)
4 Participants
1 Participants

SECONDARY outcome

Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52

Population: Patients randomized and treated at least once (at inclusion visit)

Evolution of the Near Point of Convergence (NPC)

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D0 before treatment
4.6 NPC (cm)
Standard Deviation 5.6
2.9 NPC (cm)
Standard Deviation 3.1
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D0 after treatment
1.8 NPC (cm)
Standard Deviation 2.6
0.4 NPC (cm)
Standard Deviation 1.2
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D7 before treatment
1.3 NPC (cm)
Standard Deviation 2.1
0.3 NPC (cm)
Standard Deviation 0.8
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D7 after treatment
1.0 NPC (cm)
Standard Deviation 1.8
0.1 NPC (cm)
Standard Deviation 0.4
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D52
0.9 NPC (cm)
Standard Deviation 1.8
0.4 NPC (cm)
Standard Deviation 1.0

SECONDARY outcome

Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52

Population: Patients randomized and treated at least once (at inclusion visit)

Evolution of the deviation assessed via the Cover test considering both eyes The unilateral cover test was used in this investigation, which consists into covering one eye, horizontally moving a target 5 cm in front of both eyes, and then uncovering the covered eye and observing its reaction. If it fixes the target, this is normal: there is an orthophoria. If it moves to fix the target (restitution movement), the test is positive: there is a heterophoria in near vision. Patients who had visual corrections were to keep them during the test. The test was then repeated on the other eye. The outcome of this test was a deviation value, considering both eyes, comprised between 0 (better outcome = normal fixation) and 3 (worst outcome = deviated eye without restitution movement).

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D0 before treatment
1.5 score on a scale
Standard Deviation 0.9
1.5 score on a scale
Standard Deviation 1.0
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D0 after treatment
0.9 score on a scale
Standard Deviation 1.0
1.0 score on a scale
Standard Deviation 1.0
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D7 before treatment
1.0 score on a scale
Standard Deviation 0.9
0.8 score on a scale
Standard Deviation 1.0
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D52
0.8 score on a scale
Standard Deviation 1.1
0.5 score on a scale
Standard Deviation 0.8
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D7 after treatment
0.6 score on a scale
Standard Deviation 1.0
0.6 score on a scale
Standard Deviation 0.8

SECONDARY outcome

Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52

Population: Patients randomized and treated at least once (at inclusion visit)

Evolution of the deviations assessed via Maddox rod test (horizontal deviation, vertical deviation of at least one eye)

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D7 before treatment
12 Participants
11 Participants
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D7 after treatment
10 Participants
10 Participants
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D0 before treatment
18 Participants
17 Participants
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D0 after treatment
11 Participants
13 Participants
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D52
11 Participants
14 Participants
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D0 before treatment
9 Participants
7 Participants
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D0 after treatment
4 Participants
4 Participants
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D7 before treatment
4 Participants
1 Participants
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D7 after treatment
2 Participants
1 Participants
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D52
3 Participants
1 Participants

SECONDARY outcome

Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52

Population: Patients randomized and treated at least once (at inclusion visit)

Evolution of statokinesigram area with closed eyes The statokinesigram is the projection onto a 2-dimensional space of the trajectory of the patient's center of pressure. Its area is measured in mm2. The larger the area is, the higher the patient's imbalance is. The statokinesigram area was measured using the stabilometric platform KFORCE Plates on which the patients were asked to stand for 30 s with closed eyes.

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=25 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D0 before treatment
51.9 mm2
Standard Deviation 28.9
54.9 mm2
Standard Deviation 41.4
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D52
50.9 mm2
Standard Deviation 33.9
51.9 mm2
Standard Deviation 39.5
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D0 after treatment
64.4 mm2
Standard Deviation 50.5
62.9 mm2
Standard Deviation 60.2
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D7 before treatment
51.0 mm2
Standard Deviation 34.3
56.8 mm2
Standard Deviation 33.2
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D7 after treatment
47.9 mm2
Standard Deviation 31.2
59.9 mm2
Standard Deviation 41.9

SECONDARY outcome

Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52

Population: Patients randomized and treated at least once (at inclusion visit)

Evolution of the difference between left and right distributions of patient's body weight Patient's body weight left distribution, respectively right distribution, refer to patient's body weight distribution on his/her left foot, respectively right foot. The left distribution and the right distribution are two percentages which sum makes 100%. When body weight is well distributed between left and right feet (coherent balance), the difference between left and right distributions is ≤ 5%. When body weight is not well distributed between left and right feet (uncoherent balance), the difference between left and right distributions is \> 5%. These distributions were measured using the stabilometric platform KFORCE Plates on which the patients were asked to stand for 30 s with closed eyes.

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D0 after treatment
6.9 % of body weight distribution difference
Standard Deviation 4.3
6.3 % of body weight distribution difference
Standard Deviation 5.0
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D0 before treatment
6.5 % of body weight distribution difference
Standard Deviation 4.1
6.3 % of body weight distribution difference
Standard Deviation 4.7
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D7 before treatment
5.7 % of body weight distribution difference
Standard Deviation 3.5
7.5 % of body weight distribution difference
Standard Deviation 5.7
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D7 after treatment
5.0 % of body weight distribution difference
Standard Deviation 4.7
5.2 % of body weight distribution difference
Standard Deviation 4.1
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D52
6.0 % of body weight distribution difference
Standard Deviation 5.1
6.4 % of body weight distribution difference
Standard Deviation 4.5

SECONDARY outcome

Timeframe: at Day 0 (before treatment session) and at Day 7 (after treatment session) Of note: for 46 patients, TMTB was performed before (rather than after) treatment at D7 (deviation)

Population: Patients randomized and treated at least once (at inclusion visit)

Evolution of the Trail Making Test part A and B (TMT A\&B) time to perform the task

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Evolution of Executive Function, as Assessed With the Trail Making Test Part A and B (TMT A&B)
TMTA time to perform the task: D0
19.0 s
Standard Deviation 5.4
21.2 s
Standard Deviation 7.0
Evolution of Executive Function, as Assessed With the Trail Making Test Part A and B (TMT A&B)
TMTA time to perform the task: D7
15.7 s
Standard Deviation 4.0
18.5 s
Standard Deviation 4.8
Evolution of Executive Function, as Assessed With the Trail Making Test Part A and B (TMT A&B)
TMTB time to perform the task: D0
53.5 s
Standard Deviation 20.1
50.9 s
Standard Deviation 26.6
Evolution of Executive Function, as Assessed With the Trail Making Test Part A and B (TMT A&B)
TMTB time to perform the task: D7
42.5 s
Standard Deviation 12.7
43.1 s
Standard Deviation 17.9

SECONDARY outcome

Timeframe: at baseline (which represents the patient's state before the concussion as estimated/assessed by the patient on D0), Day 0 (before treatment session), Day 7 (before treatment session), Day 14 and Day 52

Population: Patients randomized and treated at least once (at inclusion visit)

Evolution of the SCAT5 (Sport Concussion Assessment Tool - 5th edition) score The SCAT5 is a standardized tool for evaluating concussions designed for use by physicians and licensed healthcare professionals. With this tool, the patient rates the intensity of every symptom from 0 (none) to 6 (severe) using a form. This enables to calculate the total number of symptoms (subscore from 0 to 22) and the symptom severity score (subscore from 0 to 132).

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Evolution of Concussion Syndrome Symptoms
Total number of symptoms : D7 before treatment
1.2 score on a scale
Standard Deviation 2.2
1.7 score on a scale
Standard Deviation 4.2
Evolution of Concussion Syndrome Symptoms
Symptom severity score: D0 before treatment
7.5 score on a scale
Standard Deviation 7.4
10.8 score on a scale
Standard Deviation 13.2
Evolution of Concussion Syndrome Symptoms
Total number of symptoms: baseline
0.4 score on a scale
Standard Deviation 0.8
0.3 score on a scale
Standard Deviation 0.4
Evolution of Concussion Syndrome Symptoms
Total number of symptoms : D0 before treatment
4.6 score on a scale
Standard Deviation 3.7
5.5 score on a scale
Standard Deviation 4.7
Evolution of Concussion Syndrome Symptoms
Total number of symptoms : D14
0.4 score on a scale
Standard Deviation 1.1
1.3 score on a scale
Standard Deviation 4.0
Evolution of Concussion Syndrome Symptoms
Total number of symptoms : D52
0.2 score on a scale
Standard Deviation 0.6
0.8 score on a scale
Standard Deviation 3.1
Evolution of Concussion Syndrome Symptoms
Symptom severity score: baseline
0.7 score on a scale
Standard Deviation 1.5
0.4 score on a scale
Standard Deviation 0.8
Evolution of Concussion Syndrome Symptoms
Symptom severity score: D7 before treatment
2.1 score on a scale
Standard Deviation 4.2
3.5 score on a scale
Standard Deviation 11.9
Evolution of Concussion Syndrome Symptoms
Symptom severity score: D14
0.8 score on a scale
Standard Deviation 2.2
2.9 score on a scale
Standard Deviation 11.1
Evolution of Concussion Syndrome Symptoms
Symptom severity score: D52
0.3 score on a scale
Standard Deviation 1.2
2.1 score on a scale
Standard Deviation 9.2

SECONDARY outcome

Timeframe: at Day 0 (before treatment session) and at Day 52

Population: Patients randomized and treated at least once (at inclusion visit)

Evolution of the concentration of: * Anti-inflammatory cytokines InterLeukin (IL)-1 receptor antagonist, IL-4, IL-6, IL-10, IL-11 and IL-13 * S100 calcium binding protein B (S100B) * Glial Fibrillary Acidic Protein (GFAP) * Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) Of note: IL-11 and IL-13 could eventually not be analyzed due to undetectable low concentrations

Outcome measures

Outcome measures
Measure
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Evolution of the Concussion Blood Markers
GFAP : D52
67.7 pg/mL
Standard Deviation 29.6
49.8 pg/mL
Standard Deviation 21.5
Evolution of the Concussion Blood Markers
UCHL1 : D0 before treatment
11.0 pg/mL
Standard Deviation 20.4
3.9 pg/mL
Standard Deviation 4.4
Evolution of the Concussion Blood Markers
UCHL1 : D52
9.3 pg/mL
Standard Deviation 13.3
5.0 pg/mL
Standard Deviation 4.5
Evolution of the Concussion Blood Markers
IL-1RA : D0 before treatment
367.8 pg/mL
Standard Deviation 231.8
413.3 pg/mL
Standard Deviation 318.7
Evolution of the Concussion Blood Markers
IL-1RA : D52
324.2 pg/mL
Standard Deviation 122.5
452.5 pg/mL
Standard Deviation 423.8
Evolution of the Concussion Blood Markers
IL-10 : D0 before treatment
0.74 pg/mL
Standard Deviation 1.88
0.33 pg/mL
Standard Deviation 0.16
Evolution of the Concussion Blood Markers
IL-4 : D52
0.05 pg/mL
Standard Deviation 0.05
0.05 pg/mL
Standard Deviation 0.04
Evolution of the Concussion Blood Markers
IL-6 : D0 before treatment
1.25 pg/mL
Standard Deviation 2.32
2.36 pg/mL
Standard Deviation 3.44
Evolution of the Concussion Blood Markers
IL-6 : D52
0.97 pg/mL
Standard Deviation 1.85
1.35 pg/mL
Standard Deviation 2.19
Evolution of the Concussion Blood Markers
S100B : D0 before treatment
25.7 pg/mL
Standard Deviation 35.4
17.6 pg/mL
Standard Deviation 10.9
Evolution of the Concussion Blood Markers
GFAP : D0 before treatment
95.3 pg/mL
Standard Deviation 75.6
82.5 pg/mL
Standard Deviation 40.2
Evolution of the Concussion Blood Markers
IL-10 : D52
0.28 pg/mL
Standard Deviation 0.08
0.51 pg/mL
Standard Deviation 0.47
Evolution of the Concussion Blood Markers
IL-4 : D0 before treatment
0.02 pg/mL
Standard Deviation 0.01
0.02 pg/mL
Standard Deviation 0.01
Evolution of the Concussion Blood Markers
S100B : D52
25.0 pg/mL
Standard Deviation 36.0
17.2 pg/mL
Standard Deviation 10.5

Adverse Events

5 Hz-PWM

Serious events: 0 serious events
Other events: 12 other events
Deaths: 0 deaths

10 Hz-PWM

Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
5 Hz-PWM
n=26 participants at risk
RGn550 with a 5 Hz-pulsed wave mode light emission RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
10 Hz-PWM
n=24 participants at risk
RGn550 with a 10 Hz-pulsed wave mode light emission RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
Eye disorders
Photophobia
0.00%
0/26 • Throughout the investigation (from D0 to D52)
4.2%
1/24 • Number of events 1 • Throughout the investigation (from D0 to D52)
General disorders
Fatigue
0.00%
0/26 • Throughout the investigation (from D0 to D52)
4.2%
1/24 • Number of events 1 • Throughout the investigation (from D0 to D52)
General disorders
Medical device site discomfort
19.2%
5/26 • Number of events 5 • Throughout the investigation (from D0 to D52)
16.7%
4/24 • Number of events 4 • Throughout the investigation (from D0 to D52)
General disorders
Medical device site warmth
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
4.2%
1/24 • Number of events 1 • Throughout the investigation (from D0 to D52)
Infections and infestations
Tonsillitis
0.00%
0/26 • Throughout the investigation (from D0 to D52)
4.2%
1/24 • Number of events 1 • Throughout the investigation (from D0 to D52)
Injury, poisoning and procedural complications
Concussion
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
0.00%
0/24 • Throughout the investigation (from D0 to D52)
Injury, poisoning and procedural complications
Ligament sprain
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
0.00%
0/24 • Throughout the investigation (from D0 to D52)
Nervous system disorders
Headache
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
0.00%
0/24 • Throughout the investigation (from D0 to D52)
Nervous system disorders
Hypersomnia
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
0.00%
0/24 • Throughout the investigation (from D0 to D52)
Nervous system disorders
Somnolence
23.1%
6/26 • Number of events 6 • Throughout the investigation (from D0 to D52)
33.3%
8/24 • Number of events 9 • Throughout the investigation (from D0 to D52)
Psychiatric disorders
Irritability
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
0.00%
0/24 • Throughout the investigation (from D0 to D52)

Additional Information

Guillaume Blivet

REGEnLIFE

Phone: +33434481535

Results disclosure agreements

  • Principal investigator is a sponsor employee If the investigators wish to publish data from this investigation (poster, abstract, article, etc.), they must first seek approval from REGEnLIFE.
  • Publication restrictions are in place

Restriction type: OTHER